Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma

Liver Transplantation

Volumn 18, Issue 12, 2012, Pages 1406-1414

  An, Ho Jung ^a   Jang, Jeong Won ^a   Bae, Si Hyun ^a   Choi, Jong Young ^a   Yoon, Seung Kew ^a   Lee, Myung Ah ^a   You, Young Kyoung ^a   Kim, Dong Goo ^a   Jung, Eun Sun ^a  

^a The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN;

ADULT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER METASTASIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PREDICTIVE VALIDITY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; TUMOR RECURRENCE; TUMOR VOLUME;

ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 84870870922     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23512     Document Type: Article

References (30)

1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al. SEER cancer statistics review, 1975-2008. http://seer.cancer.gov/csr/1975-2008. Accessed July 2012.
2. Statistics Korea. Cancer statistics. http://kosis.kr/abroad/abroad- 03List.jsp?parentId=117-11744,H000. Accessed July 2012.
3. Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, Romeo R, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004; 126: 1005 -1014.
4. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693 -699.
5. Zimmerman MA, Ghobrial RM, Tong MJ, Hiatt JR, Cameron AM, Hong J, Busuttil RW,. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg 2008; 143: 182 -188.
6. Schwartz ME, D'Amico F, Vitale A, Emre S, Cillo U,. Liver transplantation for hepatocellular carcinoma: are the Milan criteria still valid? Eur J Surg Oncol 2008; 34: 256 -262.
7. Libbrecht L, Bielen D, Verslype C, Vanbeckevoort D, Pirenne J, Nevens F, et al. Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transpl 2002; 8: 749 -761.
8. Jonas S, Bechstein WO, Steinmüller T, Herrmann M, Radke C, Berg T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33: 1080 -1086.
9. Ridker PM, Koenig W, Fuster V,. C-reactive protein and coronary heart disease. N Engl J Med 2004; 351: 295 -298.
10. Hashimoto K, Ikeda Y, Korenaga D, Tanoue K, Hamatake M, Kawasaki K, et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 2005; 103: 1856 -1864.
11. Nagaoka S, Yoshida T, Akiyoshi J, Akiba J, Torimura T, Adachi H, et al. Serum C-reactive protein levels predict survival in hepatocellular carcinoma. Liver Int 2007; 27: 1091 -1097.
12. Jang JW, You CR, Kim CW, Bae SH, Yoon SK, Yoo YK, et al. Benefit of downsizing hepatocellular carcinoma in a liver transplant population. Aliment Pharmacol Ther 2010; 31: 415 -423.
13. Allin KH, Bojesen SE, Nordestgaard BG,. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 2009; 27: 2217 -2224.
14. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Aoki T, et al. Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol 2003; 83: 248 -252.
15. Sharma R, Kacevska M, London R, Clarke SJ, Liddle C, Robertson G,. Downregulation of drug transport and metabolism in mice bearing extra-hepatic malignancies. Br J Cancer 2008; 98: 91 -97.
16. Polterauer S, Grimm C, Seebacher V, Rahhal J, Tempfer C, Reinthaller A, Hefler L,. The inflammation-based Glasgow prognostic score predicts survival in patients with cervical cancer. Int J Gynecol Cancer 2010; 20: 1052 -1057.
17. O'Dowd C, McRae LA, McMillan DC, Kirk A, Milroy R,. Elevated preoperative C-reactive protein predicts poor cancer specific survival in patients undergoing resection for non-small cell lung cancer. J Thorac Oncol 2010; 5: 988 -992.
18. Mantovani A, Allavena P, Sica A, Balkwill F,. Cancer-related inflammation. Nature 2008; 454: 436 -444.
19. Yu H, Jove R,. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004; 4: 97 -105.
20. Castell JV, Gómez-Lechón MJ, David M, Fabra R, Trullenque R, Heinrich PC,. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 1990; 12: 1179 -1186.
21. Mundy GR,. Myeloma bone disease. Eur J Cancer 1998; 34: 246 -251.
22. Nakanishi H, Araki N, Kudawara I, Kuratsu S, Matsumine A, Mano M, et al. Clinical implications of serum C-reactive protein levels in malignant fibrous histiocytoma. Int J Cancer 2002; 99: 167 -170.
23. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006; 130: 1117 -1128.
24. Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 2001; 28: 29 -35.
25. Lin ZY, Wang LY, Yu ML, Chen SC, Chuang WL, Hsieh MY, et al. Role of serum C-reactive protein as a marker of hepatocellular carcinoma in patients with cirrhosis. J Gastroenterol Hepatol 2000; 15: 417 -421.
26. Kita Y, Iwaki Y, Demetris AJ, Starzl TE,. Evaluation of sequential serum interleukin-6 levels in liver allograft recipients. Transplantation 1994; 57: 1037 -1041.
27. Függer R, Hamilton G, Steininger R, Mirza D, Schulz F, Mühlbacher F,. Intraoperative estimation of endotoxin, TNF alpha, and IL-6 in orthotopic liver transplantation and their relation to rejection and postoperative infection. Transplantation 1991; 52: 302 -306.
28. Bertuzzo VR, Cescon M, Ravaioli M, Grazi GL, Ercolani G, Del Gaudio M, et al. Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers. Transplantation 2011; 91: 1279 -1285.
29. Sieghart W, Wang X, Schmid K, Pinter M, König F, Bodingbauer M, et al. Osteopontin expression predicts overall survival after liver transplantation for hepatocellular carcinoma in patients beyond the Milan criteria. J Hepatol 2011; 54: 89 -97.
30. Yoshida T, Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Inoue H, et al. Pigment epithelium-derived factor (PEDF) blocks the interleukin-6 signaling to C-reactive protein expression in Hep3B cells by suppressing Rac-1 activation. Life Sci 2006; 79: 1981 -1987.